Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 1:1:12.
doi: 10.1186/s40780-015-0013-8. eCollection 2015.

Adherence to changing from brand-name to generic atorvastatin in newly treated patients: a retrospective cohort study using health insurance claims

Yasunari Mano  1 , Shota Fukushima  1 , Hisayuki Kuroda  1 , Hiroyuki Ohshima  1 , Yoshinori Kato  1 , Kaori Ohuchi  1 , Kayoko Maezawa  1 , Yasuyuki Momose  1 , Shunya Ikeda  1 , Mariko Asahi  1
Affiliations

Adherence to changing from brand-name to generic atorvastatin in newly treated patients: a retrospective cohort study using health insurance claims

Yasunari Mano et al. J Pharm Health Care Sci. .

Abstract

Background: Effect of statin therapy has been reported to be associated with patient's adherence. Atorvastatin was available in Japan as a brand-name product beginning in 2000. The first atorvastatin generics were introduced in Japan in November 2011. The objective of this study was to analyze whether changing from a brand-name atorvastatin to a generic product would affect patient adherence.

Methods: We conducted a retrospective cohort study that included adult patients who received newly prescribed brand-name atorvastatin between June 1, 2011 and May 31, 2012, using a health insurance claims database in Japan. Patients were classified by the presence or absence of changing to a generic during the 6 months from December 1, 2011 to May 31, 2012 (the index period). The first prescription date for the generic or brand product during the index period was defined as the index date. Adherence to therapy was assessed by the proportion of days covered (PDC) and persistence of treatment by time to discontinuation.

Results: There were 135 patients changing to generic atorvastatin and 147 continuing with the brand-name product. There was no significant difference in decrease of PDC from pre- to post-index date between the changed cohort and continued cohort (-8.6% vs -10.3%, respectively; P = 0.443). After adjusting for baseline covariates, including adherence in pre-index date, no statistically significant differences were observed in the adjusted odds of adherence between the cohorts (adjusted odds ratio = 0.83, 95% confidence interval (CI) = 0.46-1.53). There was also no significant difference in persistence between two cohorts in the 180-day after post-index date. After analysis of a Cox proportional hazard regression model controlling for baseline covariates, including adherence in pre-index date, no statistically significant differences were observed for the hazard of non-persistence between the cohorts (adjusted hazard ratio = 0.96, 95% CI = 0.60-1.53).

Conclusions: Changing from a brand-name atorvastatin to generic product did not affect adherence for patients newly treated with atorvastatin.

Keywords: Adherence; Atorvastatin; Claim database; Cohort study; Generic substitution; Persistence; Proportion of days covered.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of the study cohort.
Figure 2
Figure 2
Difference in proportion of days covered (PDC) from pre- to post-index date for the changed and continued cohorts.
Figure 3
Figure 3
Kaplan-Meier analysis of persistence with therapy for the changed and continued cohorts. a: Time of follow up started from index date.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Dunne S, Shannon B, Dunne C, Cullen W. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol. 2013;14:1. doi: 10.1186/2050-6511-14-1. - DOI - PMC - PubMed
    1. Generic Drug Saving In the U.S. (Sixth Annual Edition. 2014) [http://www.gphaonline.org/media/cms/GPhA_Savings_Report.9.10.14_FINAL.pdf]
    1. Sander JW, Ryvlin P, Stefan H, Booth DR, Bauer J. Generic substitution of antiepileptic drugs. Expert Rev Neurother. 2010;10:1887–1898. doi: 10.1586/ern.10.163. - DOI - PubMed
    1. Himmel W, Simmenroth-Nayda A, Niebling W, Ledig T, Jansen RD, Kochen MM, et al. What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther. 2005;43:472–479. doi: 10.5414/CPP43472. - DOI - PubMed
    1. Dunne S, Shannon B, Dunne C, Cullen W. Patient perceptions of generic medicines: a mixed-methods study. Patient. 2014;7:177–185. doi: 10.1007/s40271-013-0042-z. - DOI - PubMed

LinkOut - more resources